Webcast ImageWebcast
Q2 2019 Laboratory Corporation of America Holdings Earnings Conference Call (Live)
07/25/19 at 9:00 a.m. ET
E-mail Alerts Receive E-mail Alerts | RSS RSS Feeds
Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
12/10/15LabCorp Enters into Definitive Agreement to Acquire Assets of Pathology, Inc.
BURLINGTON, N.C.--(BUSINESS WIRE)--Dec. 10, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced that it has entered into a definitive agreement to acquire substantially all of the operating assets of Pathology, Inc., including patient service centers, used to conduct Pathology, Inc.’s medical testing and services business. Pathology, Inc. is a leading full-service independent women's health laboratory, providin... 
Printer Friendly Version
11/30/15LabCorp Launches New Enhanced Report for Medical Drug Monitoring
The LabCorp MedWatch® ToxAssure® report joins a suite of proprietary decision support tools to assist clinicians in patient management BURLINGTON, N.C.--(BUSINESS WIRE)--Nov. 30, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) announced today that MedTox Laboratories (MedTox), a member of the LabCorp Specialty Testing Group, introduced a new enhanced report for medical drug monitoring, the LabCorp MedWatch® ToxAs... 
Printer Friendly Version
11/03/15LabCorp is Scheduled to Present at the 2015 Credit Suisse Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Nov. 3, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the 2015 Credit Suisse Healthcare Conference. LabCorp’s presentation is planned for Tuesday, November 10, 2015 at 1:00 PM (ET). A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. About LabCorp® ... 
Printer Friendly Version
10/26/15Laboratory Corporation of America® Holdings Announces 2015 Third Quarter Results
Q3 Net revenue of $2.3 billion, up 46% over last year Q3 Diluted EPS of $1.49; Q3 Adjusted EPS of $2.07, up 15% over last year Q3 Free Cash Flow of $220 million, up 79% over last year 2015 Adjusted EPS guidance updated to $7.80 - $7.95 from $7.75 - $8.00 BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 26, 2015-- Laboratory Corporation of America® Holdings (LabCorp® or the “Company”) (NYSE... 
Printer Friendly Version
10/23/15LabCorp Acquires Safe Foods International Holdings
Transaction Expands Capabilities in Food and Beverage product-development and product-integrity BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 23, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced the acquisition of Safe Foods International Holdings, LLC (SFIH) and its two operating companies, International Food Network (IFN) and The National Food Laboratory (The NFL). With the addition of IFN and The NFL, LabCo... 
Printer Friendly Version
10/19/15Covance Receives Frost & Sullivan Asia Pacific CRO Growth Excellence Leadership Award Two Years in a Row
BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 19, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that Covance Drug Development (“Covance”) has been awarded the 2015 Frost & Sullivan Asia Pacific CRO Growth Excellence Leadership Award. This marks the second consecutive year that Covance has received this significant recognition for its continuing efforts to expand the scope of drug development services it provides in ... 
Printer Friendly Version
10/12/15LabCorp to Offer New PD-L1 Test for Bristol-Myers Squibb’s OPDIVO® Following Collaboration in Clinical Trial
Test Launch Demonstrates that Combined LabCorp-Covance Capabilities Provide Best in Class Solutions for Development and Commercialization of Diagnostics Linked to Innovative Medicines BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 12, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced the nationwide availability of a new FDA-approved diagnostic test for PD-L1 associated with the expanded approval of Bristol-Myers... 
Printer Friendly Version
10/02/15LabCorp to Follow Pivotal Role in Clinical Trial of Merck’s Keytruda® by Offering PD-L1 Companion Diagnostic
Test Launch Demonstrates that Combined LabCorp-Covance Capabilities Make the Company Best-in-Class Partner for Development and Commercialization of Companion Diagnostics BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 2, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced the nationwide availability of a new FDA-approved companion diagnostic, the PD-L1 IHC 22C3 pharmDx assay by Dako, an Agilent Technologies compan... 
Printer Friendly Version
10/01/15Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 1, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and T... 
Printer Friendly Version
09/30/15Bode Cellmark Forensics Enters into Service Agreement in Support of Innovative Programs Dedicated to Processing Sexual Assault Kits Nationwide
BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 30, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that Bode Cellmark Forensics, a member of the LabCorp Specialty Testing Group, has entered into an agreement with the New York County District Attorney’s Office (DANY) that recognizes Bode Cellmark as a preferred forensic laboratory eligible to process untested sexual assault kits for grant recipients of DANY’s Sexual Assau... 
Printer Friendly Version
09/21/15Covance to Open Second Current Good Manufacturing Practice (cGMP) Pharmacy in U.S.
Covance is the only CRO to offer cGMP manufacturing in a U.S. Phase I Clinical Research Unit BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 21, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that Covance Drug Development will open a cGMP-compliant pharmacy at its clinical research unit in Madison, Wisconsin, allowing for on-site production of high-quality, customized pharmaceutical products for clinic... 
Printer Friendly Version
09/11/15LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 11, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) announced today that for the period of September 12, 2015 to March 11, 2016, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading ... 
Printer Friendly Version
09/10/15LabCorp is Scheduled to Present at the Morgan Stanley Global Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 10, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the Morgan Stanley Global Healthcare Conference. LabCorp’s presentation is planned for Thursday, September 17, 2015 at 1:30 PM (ET). A live audio webcast will be available via the Company website at www.labcorp.com and archived for replay. About LabCorp® Laborator... 
Printer Friendly Version
09/03/15LabCorp Expands Partnership with Perinatal Quality Foundation to Educate Patients and Healthcare Providers about Noninvasive Prenatal Testing
PQF and LabCorp Build On Established Collaboration that Promotes Appropriate Use of Innovative Technologies in Clinical Care BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 3, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today an expansion of its long-standing partnership with the Perinatal Quality Foundation (PQF) to collaborate on a new strategic initiative focused on noninvasive prenatal screening, the Genetic ... 
Printer Friendly Version
08/24/15Covance Announces Pioneering Agreement with Leading Pharmaceutical Company for Worldwide Portfolio-Level Clinical Trial Monitoring
Xcellerate® Monitoring sets new standard for risk-based monitoring of clinical trials PRINCETON, N.J.--(BUSINESS WIRE)--Aug. 24, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced that Covance Drug Development (Covance) has received a multi-year award from a leading pharmaceutical company to use Covance’s Xcellerate® platform as an exclusive central monitoring solution for their worldwide clinical trials p... 
Printer Friendly Version
08/24/15LabCorp Furthers Leadership in Personalized Medicine in Cancer by Offering Innovative VistaSeq® Hereditary Cancer Panel
VistaSeq strategically focuses on actionable genetic mutations to identify patients with increased risk of many commonly diagnosed cancers BURLINGTON, N.C.--(BUSINESS WIRE)--Aug. 24, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today the nationwide availability of its VistaSeq Hereditary Cancer Panel, a novel, 27-gene panel designed to identify patients with increased risk of breast, ovarian, melanoma, pancreatic... 
Printer Friendly Version
07/28/15LabCorp Announces New Covance Leadership
Deborah Keller to succeed Joe Herring as Covance Drug Development CEO BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 28, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) today announced that Deborah Keller will succeed Joseph Herring as Chief Executive Officer of Covance Drug Development (Covance). Mr. Herring will retire on July 31 after more than a decade as CEO. Ms. Keller joined Covance in 1987 and has held senior l... 
Printer Friendly Version
07/28/15Laboratory Corporation of America® Holdings Announces Record 2015 Second Quarter Results and Raises 2015 Adjusted EPS Guidance
Q2 Net revenue of $2.2 billion, up 46% over last year Q2 Diluted EPS of $1.64; Q2 Adjusted EPS of $2.09, up 14% over last year Q2 Free Cash Flow of $328 million, up 106% over last year 2015 Adjusted EPS guidance raised to $7.75 - $8.00 from $7.55 - $7.90 BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 28, 2015-- Laboratory Corporation of America® Holdings (LabCorp® or the “Company”) (NYSE... 
Printer Friendly Version
07/23/15Covance Opens Fit-for-Purpose Dallas Clinical Research Unit
LabCorp patient service center to be co-located in new facility to serve local patients and enhance volunteer recruitment DALLAS--(BUSINESS WIRE)--Jul. 23, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that Covance Drug Development has relocated its clinical research unit (CRU) in Dallas, TX, to a new, fit-for-purpose clinical research facility. The new unit, which opened earlier this month, has expan... 
Printer Friendly Version
07/01/15Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 1, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and T... 
Printer Friendly Version
06/04/15LabCorp Expands Access to LabCorp AccuDraw® to Support Better Patient Care
BURLINGTON, N.C.--(BUSINESS WIRE)--Jun. 4, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (LH: NYSE) today announced the expanded availability of its proprietary specimen collection and handling software, LabCorp AccuDraw®, to all clients through its website at www.LabCorp.com. Combining on-screen visual cues with step-by-step tutorials, AccuDraw is an innovative tool designed to guide the health care professional who collects patie... 
Printer Friendly Version
06/02/15LabCorp is Scheduled to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Jun. 2, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the Goldman Sachs 36th Annual Global Healthcare Conference. LabCorp’s presentation is planned for Tuesday, June 9, 2015 at 5:00 PM (ET). A live audio webcast will be available via the Company website at www.labcorp.com and archived for replay. About LabCorp® Labora... 
Printer Friendly Version
06/01/15Sysmex and LabCorp Announce a Strategic Collaboration for Blood-Based Molecular Testing Services and Products to Support the Development of Precision Medicine in Oncology
KOBE, Japan & BURLINGTON, N.C.--(BUSINESS WIRE)--Jun. 1, 2015-- Sysmex Corporation (TSE:6869) and Laboratory Corporation of America® Holdings (LabCorp®) (LH:NYSE) today announced a strategic collaboration focused on the development of blood-based molecular diagnostic tests to advance precision medicine in oncology. The collaboration combines Sysmex Inostics’ strength in the development of innovative blood-based diagnostic solutions with LabCorp's unparal... 
Printer Friendly Version
05/18/15LabCorp Announces Full Portfolio of Hepatitis C Virus Drug Resistance Assays
Expanded testing services enable precision medicine by providing clinicians with information to select optimal treatment and characterize treatment failure BURLINGTON, N.C.--(BUSINESS WIRE)--May 18, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced the launch of two new Hepatitis C Virus (HCV) drug resistance assays. The HCV NS5A and NS5B Drug Resistance Assays expand LabCorp’s portfolio of HCV resistance... 
Printer Friendly Version
05/12/15LabCorp is Scheduled to Present at the UBS Global Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--May 12, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the UBS Global Healthcare Conference. LabCorp’s presentation is planned for Tuesday, May 19, 2015 at 8:00 AM (ET). A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. About LabCorp® L... 
Printer Friendly Version
05/06/15LabCorp is Scheduled to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--May 6, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the Bank of America Merrill Lynch 2015 Health Care Conference. LabCorp’s presentation is planned for Thursday, May 14, 2015 at 11:40 AM (ET). A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. About... 
Printer Friendly Version
04/27/15Laboratory Corporation of America® Holdings Announces 2015 First Quarter Results and Raises 2015 Adjusted EPS Guidance
Q1 Net revenue of $1.8 billion, up 24% over last year Q1 Diluted EPS of $0.01; Q1 Adjusted EPS of $1.73, up 15% over last year 2015 Adjusted EPS guidance raised to $7.55 - $7.90, compared to $6.80 in 2014 BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 27, 2015-- Laboratory Corporation of America® Holdings (LabCorp® or the “Company”) (NYSE: LH) today announced results for the quarter ended March 3... 
Printer Friendly Version
04/21/15Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers
BRCA Share™ is a novel public-private initiative designed to enhance the clarity and quality of patient testing MADISON, N.J. and PARIS and BURLINGTON, N.C., April 21, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Inserm, the French National Institute of Health and Medical Research institution, today launched BRCA Share™, a novel datashare initiative they co-founded to provide scientists and laboratory organizations ... 
Printer Friendly Version
04/09/15Bode Technology Supports Identification of Missing Persons in Cyprus Using DNA
BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 9, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (LH: NYSE) today announced that its wholly-owned subsidiary Bode Cellmark Forensics (Bode Cellmark), a member of the LabCorp Specialty Testing Group, is cooperating with the Committee on Missing Persons (CMP) in Cyprus in its mission of exhumation, identification, and return of remains of missing persons in Cyprus. The CMP in Cyprus is a bi-com... 
Printer Friendly Version
04/01/15Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 1, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and Th... 
Printer Friendly Version
03/12/15LabCorp Presents New Findings on HIV-1 and HCV Antiviral Drug Resistance at the 2015 Conference on Retroviruses and Opportunistic Infections
State of the art genetic and cell-based assays enable comprehensive characterization of resistance to new drugs and new drug classes BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 12, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that Monogram Biosciences, Inc., a member of the LabCorp Specialty Testing Group, presented two new studies characterizing HIV-1 and HCV antiviral drug resistance at the 2015 Confer... 
Printer Friendly Version
03/11/15LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 11, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that for the period of March 12, 2015 to September 11, 2015, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading... 
Printer Friendly Version
03/04/15LabCorp Contributes to Clinical Research Collaborations Directed at Advancing Treatment of Breast Cancer and Viral Hepatitis
Studies Promote Personalized Medicine and Advance Public Health Initiatives BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 4, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today highlighted clinical research efforts in oncology and viral hepatitis that demonstrate its commitment to novel diagnostic capabilities and unique bioinformatics resources to enhance patient care in today’s rapidly evolving healthcare system. ... 
Printer Friendly Version
03/03/15LabCorp is Scheduled to Present at the Barclays Capital 2015 Global Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 3, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the Barclays Capital 2015 Global Healthcare Conference. LabCorp’s presentation is planned for Tuesday, March 10, 2015 at 8:30 AM (Eastern Time). A live audio webcast of the presentation will be available via the Company Web site at www.labcorp.com and archived for replay. ... 
Printer Friendly Version
02/20/15Laboratory Corporation of America® Holdings Announces 2014 Fourth Quarter and Full Year Results and Provides 2015 Guidance
Strong Q4 volume drives sales of $1.5 billion Diluted Q4 EPS of $1.39; Adjusted Q4 EPS of $1.65 Q4 Operating Cash Flow of approximately $214 million Q4 Free Cash Flow of approximately $167 million Announces Project LaunchPad, its enterprise-wide business process improvement initiative 2015 Adjusted EPS guidance of $7.35 - $7.70, inclusive of Covance as of... 
Printer Friendly Version
02/19/15LabCorp Completes Acquisition of Covance
Combination Creates Leading Healthcare Diagnostics Company & End-to-End Solutions for Drug Development and Commercialization BURLINGTON, N.C.--(BUSINESS WIRE)--Feb. 19, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced the completion of its acquisition of Covance Inc., following its entry into a definitive purchase agreement on November 2, 2014. At closing, the purchase consideration was valued at ... 
Printer Friendly Version
02/10/15LabCorp Launches New Patient-Centric Diabetes Report
BURLINGTON, N.C.--(BUSINESS WIRE)--Feb. 10, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today the availability of a new Diabetes Patient Education report for type 2 diabetes patients that aligns with the American Diabetes Association (Association) “Standards of Medical Care in Diabetes – 2015,” which was published as a supplement to the January 2015 edition of the Association’s Diabetes Care journal. LabCorp’... 
Printer Friendly Version
01/21/15LabCorp Prices $500,000,000 in 2.625% Senior Notes Due 2020, $500,000,000 in 3.200% Senior Notes Due 2022, $1,000,000,000 in 3.600% Senior Notes Due 2025 and $900,000,000 in 4.700% Senior Notes Due 2045
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 21, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that it has priced its offering of $2.9 billion in senior notes. The offering consists of four tranches: $500,000,000 aggregate principal amount of 2.625% Senior Notes due 2020 (the “2020 Notes”), $500,000,000 aggregate principal amount of 3.200% Senior Notes due 2022 (the “2022 Notes”), $1,000,000,000 aggregate prin... 
Printer Friendly Version
01/21/15LabCorp Announces Proposed Sale of Senior Notes
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 21, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that it plans to offer, subject to market and other conditions, senior notes that are expected to be issued in four tranches with maturities of 5,7,10 and 30 years, respectively (the “Notes”). The Notes will be senior unsecured obligations and will rank equally with LabCorp’s existing and future senior unsecured debt. ... 
Printer Friendly Version
01/06/15LabCorp is Scheduled to Present at the 33rd Annual J.P. Morgan Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 6, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. LabCorp’s presentation is planned for Tuesday, January 13, 2015 at 2:00 p.m. (PST). A live audio webcast of the presentation will be available via the Compa... 
Printer Friendly Version
01/02/15Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 2, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and The Bank of New York Mellon, as trustee (Trustee)... 
Printer Friendly Version
Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Tear Sheet